End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
19.47 CNY | +0.05% | +1.20% | -12.02% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.02% | 4.92B | C- | ||
-3.93% | 86.16B | A- | ||
+2.76% | 40.17B | A- | ||
-17.49% | 31.47B | B- | ||
+54.44% | 25.24B | A | ||
-13.13% | 15.82B | C | ||
-9.12% | 11.96B | D+ | ||
-15.45% | 11.89B | B- | ||
-42.56% | 11.61B | B | ||
+4.87% | 8.84B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 002007 Stock
- Ratings Hualan Biological Engineering Inc.